What did @dpropeps actually say?
The creator laid out a practical starter protocol: mix 5mg CJC-1295 and 5mg ipamorelin with 3mL bacteriostatic water, draw 0.18mL (18 units) for a 300mcg dose of each, inject once daily before bed on an empty stomach, and run 16 weeks on with 4 weeks off. Expected benefits listed were better sleep in week one, deeper recovery, fat loss, and muscle retention. Side effects were described as "usually mild" — water retention and tingling.
That's a lot of specific instructions delivered in under two minutes to 42,800 viewers, some of whom are presumably injecting based on this advice. The question is whether the claims hold up.
Does the science back this up?
Partially, but the gap between what exists in research and what the video implies is significant. The growth hormone secretagogue mechanism is real, but the human clinical evidence is thinner than the confident tone suggests.
CJC-1295 (a GHRH analogue) and ipamorelin (a ghrelin receptor agonist) work on complementary pathways to stimulate pulsatile GH release. The dual-peptide approach is pharmacologically coherent. Teichman et al. (2006, Journal of Clinical Endocrinology and Metabolism) showed CJC-1295 produced dose-dependent GH and IGF-1 increases in healthy adults. Raun et al. (1998, European Journal of Endocrinology) demonstrated ipamorelin's selective GH-releasing properties in animals with minimal cortisol or prolactin effects compared to other secretagogues.
The sleep claim has some indirect support. GH secretion is highest during slow-wave sleep, and administering secretagogues before bed is consistent with that physiology. But no published human RCT has specifically measured subjective sleep quality improvement from this combination in the first week. The fat loss and muscle retention framing leans heavily on GH's known metabolic roles, extrapolated beyond what combination peptide trials have actually shown in healthy individuals.
What did they get wrong (or right)?
The dose math is correct. 5mg in 3mL gives 1.67mcg/uL, so 180uL delivers approximately 300mcg. That arithmetic checks out. The pre-bed, fasted timing is also consistent with established GH secretion physiology and is the approach used in most research protocols.
Where the video oversimplifies: the "you can run it every single day" advice dismisses a real concern about GH receptor desensitization. Sigalos and Pastuszak (2018, Sexual Medicine Reviews) noted that chronic continuous stimulation of GH pathways raises questions about tachyphylaxis. The 5-on/2-off pattern the creator waves off exists precisely because some clinicians want periodic receptor recovery. Dismissing it without explanation is not good guidance.
The side effect picture is also too clean. Water retention and tingling are real, but the list omits injection site reactions, potential fasting insulin changes, and the fact that elevated IGF-1 over 16 weeks has not been studied for long-term safety in non-deficient healthy adults. Claiming side effects are "usually mild" without that context is incomplete.
What should you actually know?
These are not FDA-approved drugs. CJC-1295 and ipamorelin are available in the U.S. primarily as compounded peptides, meaning quality, sterility, and concentration vary by pharmacy. The FDA has taken regulatory action against certain compounded peptides, and the legal landscape for these compounds has shifted multiple times.
The 16-week duration is not clinically validated for this combination in healthy adults. It appears to be community convention, not a protocol derived from controlled trials. Teichman et al.'s CJC-1295 study ran dosing intervals over weeks, not a continuous 16-week self-injection course.
Anyone considering this should know that a telehealth physician evaluation, baseline IGF-1 labs, and follow-up bloodwork are the standard of care for growth hormone axis interventions. A 42-second dose walkthrough on Instagram is not a substitute for that. The peptides may have real utility in appropriate clinical contexts. That does not make unsupervised self-dosing based on social media content a reasonable approach.
- CJC-1295 and ipamorelin are not approved by the FDA for the uses described.
- Compounded peptide quality is not federally standardized.
- IGF-1 monitoring during extended use is clinically warranted.
- Individual response varies based on age, body composition, existing GH levels, and other factors not addressed in this video.